

1 **Seroprevalence of IgG antibodies against SARS coronavirus 2 in Belgium – a prospective cross-**  
2 **sectional study of residual samples**

3 Herzog Sereina, PhD <sup>1\*</sup>, De Bie Jessie, PhD <sup>2,3\*</sup>, Abrams Steven, Prof <sup>3,4</sup>, Wouters Ine, PhD <sup>2</sup>, Ekinci  
4 Esra, MSc <sup>2</sup>, Patteet Lisbeth, PhD <sup>5</sup>, Coppens Astrid, MSc <sup>5</sup>, De Spiegeleer Sandy, MSc <sup>6</sup>, Beutels  
5 Philippe, Prof <sup>1</sup>, Van Damme Pierre, Prof <sup>2</sup>, Hens Niel, Prof <sup>1,4</sup>, Theeten Heidi, Prof <sup>2</sup>

6 <sup>1</sup> *Centre for Health Economics Research and Modelling of Infectious Diseases (CHERMID), Vaccine*  
7 *& Infectious Disease Institute (VAXINFECTIO), University of Antwerp, B-2610 Wilrijk, Belgium.*

8 <sup>2</sup> *Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of*  
9 *Antwerp, B-2610 Wilrijk, Belgium*

10 <sup>3</sup> *Global Health Institute, Department of Epidemiology and Social Medicine, University of Antwerp, B-*  
11 *2610 Wilrijk, Belgium.*

12 <sup>4</sup> *Data Science Institute, I-BioStat, UHasselt, B-3500 Hasselt, Belgium.*

13 <sup>5</sup> *Algemeen Medisch Laboratorium (AML), Sonic Healthcare, B-2020 Antwerp, Belgium.*

14 <sup>6</sup> *Laboratoire Luc OLIVIER, B-5380 Fernelmont, Belgium.*

15

16 \* Herzog Sereina and De Bie Jessie contributed equally to this paper

17

18 Corresponding author:

19 Prof. Heidi Theeten, Centre for the Evaluation of Vaccination, Vaccine and Infectious Diseases  
20 Institute, University of Antwerp, Universiteitsplein, 1 B-2610 Wilrijk, Belgium;  
21 [heidi.theeten@uantwerpen.be](mailto:heidi.theeten@uantwerpen.be); +32 3 265 28 61

## 22 **Research in context**

### 23 **Evidence before this study**

24 This is the first study reporting seroprevalence and seroincidence of IgG against SARS-CoV-2 in the  
25 Belgian population. Worldwide, PCR tests are being performed to identify mainly sick people  
26 suffering from COVID-19. However, seroprevalence studies are important and feasible to study the  
27 proportion of the population that has already been in contact with the virus, which helps to understand  
28 the likelihood of asymptomatic infections or infections with mild symptoms.

29 From 11 March to 11 May, updates on the COVID-19 pandemic by the World Health Organisation as  
30 well as bulletins from the Belgian Scientific Institute for Public Health, Sciensano, were consulted  
31 daily. Press releases from all over the world were monitored during that period. Google, PubMed as  
32 well as the pre-print server medrxiv were consulted by searching the terms “seroprevalence SARS-  
33 CoV-2” and “COVID-19”,

### 34 **Added value of this study**

35 This study reports that seroprevalence increased in Belgium from 2.9% (95% CI 2.3 to 3.6) to 6.0%  
36 (95% CI 5.1 to 7.1) over a period of 3 weeks during lockdown (30 March-5 April 2020 & 20-26 April  
37 2020) with seroincidence estimate of 3.1% (95% CI 1.9 to 4.3). Moreover, a significant increase in  
38 seroprevalence in the age categories 20-30 and  $\geq 80$  and within each sex were reported.

### 39 **Implications of all the available evidence**

40 Seroprevalences worldwide indicate that an increasing fraction of the population has already been  
41 exposed to SARS-CoV-2. The continuous monitoring of seroprevalences is valuable to calibrate the  
42 response to the epidemic and to guide policy makers to control the epidemic wave and potential future  
43 waves and to avoid a deconfinement strategy leading to a rebound. However, it seems likely that  
44 natural exposure during this pandemic might not soon deliver the required level of herd immunity and  
45 there will be a substantial need for mass vaccination programmes to save time and lives.

46 **Abstract**

47 **Background** In the first weeks of the COVID-19 epidemic in Belgium, a repetitive national serum  
48 collection was set up to monitor age-related exposure through emerging SARS-CoV-2 antibodies.  
49 First objective was to estimate the baseline seroprevalence and seroincidence using serial survey data  
50 that covered the start of a national lock-down period installed soon after the epidemic was recognized.

51 **Methods** A prospective serial cross-sectional seroprevalence study, stratified by age, sex and region,  
52 started with two collections in April 2020. In residual sera taken outside hospitals and collected by  
53 diagnostic laboratories, IgG antibodies against S1 proteins of SARS-CoV-2 were measured with a  
54 semi-quantitative commercial ELISA. Seropositivity (cumulative, by age category and sex) and  
55 seroincidence over a 3 weeks period were estimated for the Belgian population.

56 **Findings** In the first collection, IgG antibodies were detected in 100 out of 3910 samples, whereas in  
57 the second collection 193 out of 3391 samples were IgG positive. The weighted overall seroprevalence  
58 increased from 2.9% (95% CI 2.3 to 3.6) to 6.0% (95% CI 5.1 to 7.1), reflected in a seroincidence  
59 estimate of 3.1% (95% CI 1.9 to 4.3). Age-specific seroprevalence significantly increased in the age  
60 categories 20-30, 80-90 and  $\geq 90$ . No significant sex effect was observed.

61 **Interpretation** During the start of epidemic mitigation by lockdown, a small but increasing fraction of  
62 the Belgian population showed serologically detectable signs of exposure to SARS-CoV-2.

63 **Funding** This independent researcher-initiated study acknowledges financial support from the  
64 Antwerp University Fund, the Flemish Research Fund, and European Horizon 2020.

## 65 **Introduction**

66 A cluster of 27 individuals who visited the Huanan seafood market was diagnosed with pneumonia of  
67 an unknown aetiology in December 2019 in Wuhan (Hubei Province, China).<sup>1</sup> Subsequent isolation  
68 and sequencing of the virus revealed a novel coronavirus: severe acute respiratory syndrome-  
69 coronavirus-2 (SARS-CoV-2), of which bats are the most likely host.<sup>2</sup> It is the third coronavirus  
70 crossing species to infect human populations, the previous ones being SARS-CoV and MERS-CoV in  
71 China (2002) and in Middle Eastern countries (2012), respectively.<sup>3</sup> Human-to-human transmission of  
72 the virus was thought to be limited, however, the emergence of SARS-CoV-2 rapidly turned into a  
73 public health emergency of international concern, which indicates efficient human-to-human  
74 transmission.<sup>4,5</sup> The World Health Organization (WHO) announced on 11 March 2020, that the  
75 outbreak became pandemic.<sup>6</sup> Clinical symptoms caused by the virus include loss of taste and smell,  
76 fever, malaise, dry cough, shortness of breath, and respiratory distress. Reported illnesses have ranged  
77 from very mild to severe (from progressive respiratory failure to death).<sup>2</sup> In addition, increasing age,  
78 male sex, smoking, and comorbidities such as cardiovascular diseases and diabetes have been  
79 identified as risk factors for developing severe illness.<sup>7</sup> As of 26 April 2020, a total of 2,796,453  
80 confirmed cases in 215 countries were reported to be infected by SARS-CoV-2 causing coronavirus  
81 disease 2019 (COVID-19) and resulting in 193,799 deaths.<sup>5</sup>

82 Currently, there is no vaccine or medical treatment available to protect against COVID-19. Therefore,  
83 unprecedented measures such as physical distancing, large-scale isolation and closure of borders,  
84 schools and workplaces were considered in many countries to mitigate the spread of the disease and to  
85 reduce the corresponding pressure on the respective healthcare systems.

86 In Belgium, the first confirmed case was reported on 4 February 2020, an asymptomatic person  
87 repatriated from Wuhan.<sup>8</sup> The first locally transmitted cases were confirmed on 2 March 2020.  
88 Thereafter, the number of confirmed COVID-19 cases rapidly increased. The Belgian Scientific  
89 Institute for Public Health, Sciensano, reported that as of 30 April 2020, 48,519 cases were confirmed  
90 (0.4% of the Belgian population and 14.1% of the tested individuals) of which 7594 died. The  
91 majority of the reported Belgian cases are in the age category of 80-89 years (20.4%; 9905/48,519).<sup>9</sup>

92 Knowledge on and quantification of the age-specific susceptibility to SARS-CoV-2, and its evolution  
93 over time, related to control measures that have been taken, is tremendously important to guide policy  
94 makers aiming to control the epidemic wave and potential future waves as a result of an insufficient  
95 herd immunity level in the population. These needs were translated into the following research  
96 objectives: (1) to constitute a national serum bank on a periodic basis (cross-sectional study design) in  
97 order to estimate the seroprevalence in Belgium and its regions and to follow-up trends herein over  
98 time and (2) to estimate the age-specific prevalence of antibodies in order to identify age groups that  
99 have been infected versus those that are still susceptible as a function of time. The current study  
100 presents background seropositivity (overall, by age category, and sex) in the Belgian population using  
101 serial serological survey data from the first two collection periods (30 March – 5 April 2020, 20 – 26  
102 April 2020), that covered the first weeks of a lockdown period installed by the Belgian government  
103 from 13 March 2020 onwards.

## 104 **Methods**

### 105 **Study design**

106 This prospective cross-sectional seroprevalence study is conducted in individuals aged 0-101 years. A  
107 serum bank covering all Belgian regions was constituted by collecting residual sera from ten private  
108 diagnostic laboratories in Belgium. In each collection period, sera are collected over one week's time.  
109 In this study we report on the first two collection periods, 30 March-5 April 2020 (mainly representing  
110 exposure before the lockdown) and 20-26 April 2020 (representing exposure prior to and during the  
111 start of the lockdown period). In total, up to five collection periods with intervals of three to four  
112 weeks are foreseen, with the last one conducted by the end of June. To avoid overrepresentation of  
113 subjects with acute and/or severe illness, samples collected in hospitals were excluded. Each  
114 laboratory was allocated a fixed number of samples per age group (defined in 10-year age bands: 0-9,  
115 10-19, etc., with the oldest age group consisting of subjects aged  $\geq 90$  years), per region (Wallonia,  
116 Flanders, Brussels), and per periodical collection period. The number of samples was stratified by sex,  
117 to obtain equal numbers of males and females in each age group.

118 The study protocol was approved by the Ethics Committee of the University Hospital Antwerp-  
119 University of Antwerp on March 30, 2020 (ref 20/13/158; Belgian Number B3002020000047) and  
120 agreed with inclusion without informed consent, on the condition of the samples being collected  
121 unlinked and anonymously.

### 122 **Sample size**

123 The sample size per periodical collection has been calculated according to: (1) previous experience  
124 with various age-specific analyses of seroprevalence data in Belgium,<sup>10</sup> (2) estimates of the number of  
125 COVID-19 infected people in Belgium and (3) the estimated evolution of the epidemic curve. Based  
126 on case numbers (hospitalized cases confirmed with COVID-19), the overall prevalence of COVID-19  
127 infection at the start of the study was estimated to be about 0.4% (42,797/11,460,000). Based on the  
128 hypothesized overall prevalence, a total sample size of 4000 in the first collection round ensures the  
129 estimation of the overall prevalence with a margin of error of 0.2%; the precision regarding the age-

130 specific prevalence estimates is lower due to the division of samples across the age groups. However,  
131 an increase in prevalence was expected during the study period. In total, up to 14,000 sera were  
132 planned to be collected, distributed over five periodic collections, and for each data collection target  
133 numbers per age group were adapted according to feasibility, sample availability and aiming at  
134 maximizing precision and assessing the impact of a change in epidemic control policy. The actual  
135 number of samples collected per period are indicated in the result section.

### 136 **Sample preparation and analysis**

137 After centrifugation of blood samples, selected residual sera (minimum 0.5 mL) were kept in the  
138 fridge (4-8°C) for a maximum of 14 days and finally stored at -20°C. Serology results were obtained  
139 through a semi-quantitative test kit (EuroImmun, Luebeck, Germany), measuring IgG antibodies  
140 against S1 proteins of SARS-CoV-2 in serum (ELISA). The test was performed as previously  
141 described by Lassaunière *et al.*<sup>11</sup> The Dutch Taskforce Serology has compared all available data using  
142 the EuroImmun ELISA and determined a specificity of 99,2% and sensitivity ranging from 64.5% to  
143 87,8% in pauci-symptomatic patients and patients with severe disease, respectively, using samples  
144 from patients >14 days after onset of disease symptoms<sup>12</sup>. Presence of detectable IgG antibodies  
145 indicates prior exposure to SARS-CoV-2, an infection which may be resolved or is still resolving, and  
146 possibly protection against reinfection,<sup>11,13</sup>

### 147 **Data management**

148 Data collected for each sample include: unique sample code, sample date, age (in years), sex, and  
149 postal code of the place of residence. From the second collection period onwards, for each sample it is  
150 recorded whether or not a COVID-19 diagnostic (PCR) test was requested at the collecting  
151 laboratories, and whether or not the test result was positive. Samples were delivered anonymously to  
152 the investigators. Triage and check for duplicates was done in the collecting laboratories before  
153 anonymization.

154 Each collection period, data were checked for completeness (based on age, sex, and postal code).  
155 Serological results (SARS-CoV-2 antibodies) were linked to the database based on the sample code.

156 No further data entry was required. All files were kept on a secured server at the University of  
157 Antwerp, with restricted access. Data will be stored for 20 years.

### 158 **Statistical analysis**

159 The serostatus of an individual was considered to be positive if the measured IgG OD values were  
160  $\geq 1.1$ , equivocal IgG values were considered negative. Crude seroprevalence estimates are displayed  
161 with exact Clopper-Pearson 95% confidence intervals (CIs). For all further analyses, the overall  
162 seroprevalence estimate and estimates by 10-year age bands, and sex for each collection period were  
163 derived by fitting generalized linear models (binomial outcome distribution) to the serostatus of the  
164 weighted samples for each collection period. Weighted seroprevalence estimates are stated with the  
165 asymptotic 95% CIs using the design-based standard errors. The overall seroincidence estimate and  
166 estimates by 10-year age bands, and sex between collection periods were derived by calculating the  
167 difference between the corresponding estimated seroprevalence from generalized linear models  
168 (binomial outcome distribution) fitted to the serostatus of the weighted samples including an  
169 interaction term for the collection period. Weighted seroincidence estimates are displayed with  
170 corresponding 95% CIs constructed using the multivariate delta method to quantify the variability  
171 thereabout.<sup>14</sup>

172 We assigned for each collection period weights to the samples such that they replicate the Belgian  
173 population structure according to age, sex and provinces for 2020.<sup>15</sup> Weights are computed by  
174 comparing the sample and population frequencies, i.e. we used a complete cross frequency table for  
175 sex and 10-year age bands and a marginal distribution for the provinces. Weights were trimmed to a  
176 maximum value of 3 to reduce the influence of samples in under-represented strata. All analyses were  
177 done with the statistical software R (version 3.6.3) using the package survey (version 4.0).<sup>16,17</sup>

### 178 **Role of the funding source**

179 The funders had no role in study design, data collection, data analysis, data interpretation, writing or  
180 submitting of the report. The corresponding author had full access to all the data in the study and had  
181 final responsibility for the decision to submit for publication.



## 182 **Results**

183 A total of 7307 serum samples were collected over two periods (30 March-5 April 2020 and 20-26  
184 April 2020) to measure the anti-SARS-Cov2 IgG sero-status. The regional, age, and sex distribution of  
185 these samples are shown in Table 1. More Flemish samples were collected in the first period compared  
186 to the second period (56.1% in period 1 vs 45.8% in period 2), but this was taken into account in the  
187 estimation of the weighted seroprevalences. The median age of the study population was 55 years and  
188 49 years in the respective collection periods. The planned 400 samples per age category in the first  
189 collection round was not reached for the age categories 0-20 and  $\geq 90$ , however, target numbers per age  
190 group were adapted according to feasibility and maximizing precision. Slightly more serum samples  
191 originated from females in both collection periods. Figure 1 shows that the samples were collected  
192 throughout Belgium (panel A and C) and that positive samples were spread over municipalities across  
193 Belgium in both collection periods (panel B and D).

194 In the first collection period, IgG antibodies were detected in 100 out of 3910 samples, whereas in the  
195 second collection period 193 out of 3397 samples had IgG antibodies. This corresponds to a crude  
196 seroprevalence estimate of 2.6% (95% CI 2.1 to 3.1) and 5.7% (95% CI 4.9 to 6.5) in both collection  
197 periods, respectively. The weighted overall seroprevalence showed a significant increase from 2.9%  
198 (95% CI 2.3 to 3.6) to 6.0% (95% CI 5.1 to 7.1) over a period of 3 weeks (Figure 2, panel A) which is  
199 also shown by the overall seroincidence estimate of 3.1% (95% CI 1.9 to 4.3) (Figure 2, panel D). A  
200 significant increase in seroprevalence was observed in the age categories 20-30, 80-90, and  $\geq 90$  as  
201 indicated by the seroincidence estimates (Figure 2, panel B+E). For example, in the 20-30 year olds,  
202 seroprevalence increased from 1.4% (95% CI 0.6 to 3.1) to 7.6% (95% CI 4.9 to 11.9) which is  
203 reflected in the corresponding seroincidence estimate of 6.2% (95% CI 2.7 to 9.8). The seroprevalence  
204 estimates ranged between 1.4% (20-30 years) and 5.9% (0-10 years) in collection period 1 and  
205 between 3.8% (60-70 years) and 15.1% ( $\geq 90$  years) in the second period. Among age categories in  
206 collection period 2, the seroprevalence of the oldest category ( $\geq 90$  years) significantly differed from  
207 the seroprevalences of the age categories 10-20 years, 30-40 years, 60-70 years, and 70-80 years.  
208 Within each sex a significant increase in seroprevalence was observed (Figure 2, panel C+F) but no

209 differences between males and females in seroincidence or in seroprevalence in any of the periods  
210 were identified.

## 211 Discussion

212 This study reports seroprevalence and seroincidence estimates of IgG antibodies against SARS-CoV-2  
213 for Belgium based on 7307 residual sera collected by diagnostic laboratories over 30 March – 5 April  
214 and 20 – 26 April 2020, shortly after the start of a national lockdown period to control the emerging  
215 COVID19 epidemic. The overall seroprevalence in Belgium was estimated to be 2.9% (95% CI 2.3 to  
216 3.6) and 6.0% (95% CI 5.1 to 7.1) in the first and second collection period. As such, seroprevalence  
217 estimates doubled over a period of 3 weeks. More specifically, elderly ( $\geq 80$  years old) and the 20-30  
218 year old subjects showed higher seroprevalence estimates in the second collection period compared to  
219 the first one.

220 Because little is known about the medical history of subjects of whom residual samples are collected,  
221 any potential bias is difficult to identify and control for when estimating seroprevalence. In this study,  
222 the potential for selection bias was reduced by enrolling multiple laboratories in Belgium with samples  
223 collected from ambulatory patients visiting their doctor for any reason. Samples originating from  
224 hospitals were excluded from the study to avoid over selection of subjects with acute and/or severe  
225 illness. Residual sera have previously been used in serosurveillance studies in Belgium<sup>10</sup> as in other  
226 countries, and can provide valuable and representative information on immunity against infectious  
227 diseases for the general population<sup>18</sup>.

228 Stringent containment measures were enforced in Belgium as of 13 March 2020. These included travel  
229 bans, closures of schools, shops, factories and social gatherings in an effort to contain the spread of  
230 COVID-19 and decrease its burden on public health. These intervention measures slowed down the  
231 number of COVID-19 patients that were hospitalized daily. By the first two weeks of the lockdown  
232 (25 March 2020), over 500 cases were hospitalized daily, and this growth rate was halved 4 weeks  
233 later.<sup>9</sup> As of 30 April 2020, 0.1% of the Belgian population had been hospitalized for COVID-19  
234 ( $15,239/11.46 \times 10^6$ ) and 0.4% of the Belgian population had tested positive for SARS-CoV-2  
235 ( $48,519/11.46 \times 10^6$ ) on a total of 345,047 screened patients.<sup>9</sup> Clearly, the reported numbers of COVID-  
236 19 confirmed cases represent an underestimation and were influenced by the testing policy as testing  
237 was initially focused on the most severe cases, presenting to hospitals. Asymptomatic and mild cases

238 were less likely reported as at different stages of the first epidemic wave, varying proportions of  
239 symptomatic cases presented to primary care, and varying proportions of these cases were tested. The  
240 estimated seroprevalence in the week of 20-26 April 2020 (6.0%, 95% CI 5.1 to 7.1) indicates that far  
241 more people had generated antibodies against SARS-CoV-2 and thus had been in contact with the  
242 virus than what is expected from the number of COVID-19 confirmed cases reported in Belgium on 30  
243 April 2020 (0.4%). The current seroprevalence study measuring IgG antibodies against SARS-CoV-2  
244 in the general population thus provides information that, in combination with the reported confirmed  
245 COVID-19 cases, allows estimating the total number of SARS-CoV-2 infections in Belgium.

246 From the above it is clear that determination of the extent of spread of SARS-CoV-2 is a challenge as  
247 typically symptomatic patients are diagnosed. In contrast, mainly asymptomatic and pauci-  
248 symptomatic subjects were included in the current study suggesting an **underestimation** of the  
249 cumulative incidence of SARS-CoV-2 infection in the population. Moreover, the sensitivity of the  
250 serological test used depends on the time since the onset of symptoms,<sup>11</sup> thereby preventing a fraction  
251 of the infected subjects to test seropositive if not infected long enough prior to testing. By day 14 after  
252 symptom onset, IgG against SARS-CoV-2 are detectable in serum of the majority of patients.<sup>2</sup>  
253 Possibly, recent SARS-CoV-2 infected subjects may have been included in the current seroprevalence  
254 study of whom antibodies were not yet detectable in blood. In addition, SARS-CoV-2 infected  
255 subjects with mild or no symptoms of whom it is reported that they may develop low or no antibodies  
256 against SARS-CoV-2, may have been included in this study as well.<sup>19</sup> As such, these pauci-  
257 symptomatic subjects may have been falsely seronegative, and thus also cause underestimation of the  
258 incidence of infection. This may be partly accounted for in future reports, when available information  
259 on whether a diagnostic COVID-19 test was performed together with the outcome of the test will be  
260 recorded.

261 A correlation between **age** and neutralizing antibody level was observed in COVID-19 recovered  
262 patients in the study of Wu *et al.*<sup>20</sup> Significantly higher IgG values were seen in elderly patients  
263 compared to younger patients with similar disease severity, possibly due to a stronger innate immune  
264 response in elderly patients.<sup>20,21</sup> We could not observe any clear age-trend in IgG values in the current

265 study, possibly due to the low numbers (n=2-29) of seropositive cases per age category. Gaining  
266 insights into the IgG values against SARS-CoV-2 by age will be facilitated as the total number of  
267 collected samples increases with every collection period.

268 Male **sex** has been identified as a risk factor for severe COVID-19 disease. However, SARS-CoV-2  
269 susceptibility is similar for males and females and thus no difference in seroprevalence is to be  
270 expected based on sex.<sup>22</sup> Nevertheless, one could argue that symptomatology goes hand-in-hand with  
271 the initiation and extent of a humoral response. Since probably no severe symptomatic cases were  
272 included in this study, any effect of disease severity and concomitant extent in humoral response in  
273 males is not detectable.

274 The uneven infection rate of SARS-CoV-2 hampers the comparison of seroprevalence between  
275 countries. A meta-analysis by Levesque et al.<sup>23</sup> reported a seroprevalence of 14% in Gangelte  
276 (Germany, 30 March – 10 April 2020, lockdown by 22 March, 100 households). A Swiss study  
277 (Geneva, 6 - 26 April 2020, physical distancing measures by 20 March, 633 households) estimated an  
278 increasing seroprevalence, from 3.1% (95% CI 0.2 to 5.99, n=343) to 6.1% (95% CI 2.6 to 9.33,  
279 n=416) up to 9.7% (95% CI 6.1 to 13.11, n=576) in three subsequent weeks.<sup>24</sup> A weekly serological  
280 study in Sweden (country in ‘low-scale’ lockdown) showed a seroprevalence of 7.3% (n=1104) in  
281 Stockholm in the week of 27 April 2020.<sup>25</sup> Other preliminary serological surveys from EU Member  
282 States and USA reported that 1.0 - 3.4% of asymptomatic adult blood donors had antibodies against  
283 SARS-CoV-2 virus in the period 20 March – 12 April 2020 (i.e. first month in lockdown in reported  
284 countries).<sup>26</sup> These seroprevalence estimates, as well as the seroprevalence estimates obtained in the  
285 current study provide a consistent picture and increasing incidence of infections across Europe and  
286 North America.

287 Next to defining and monitoring the extent of virus spread in a population, evaluating seroprevalence  
288 also possibly identifies protective immunity of individuals after infection. The WHO stipulates that as  
289 of 24 April 2020, no study has evaluated whether the presence of antibodies to SARS-CoV-2 confers  
290 protection against subsequent infection by this virus in humans.<sup>27</sup> Furthermore, even if presence of  
291 detectable antibodies against SARS-CoV-2 would be shown to be protective, recent calculations

292 reveal that we are still far away from natural herd immunity. Based on the estimated basic  
293 reproduction number ( $R_0$  ranges from 1.4 to 3.9),<sup>28</sup> 50 – 75 % of a population would need to have  
294 protective immunity in order to achieve herd immunity mitigating subsequent waves of COVID-19.<sup>29</sup>  
295 Currently, many countries including Belgium are collecting seroprevalence data to guide policy  
296 decisions, but it seems likely that natural exposure during this pandemic might not soon deliver the  
297 required level of herd immunity and there will be a substantial need for mass vaccination programmes  
298 to save time and lives.<sup>30</sup>

## 299 **Conclusion**

300 Seroprevalence studies are important and feasible to study the proportion of the population that has  
301 already been in contact with the virus, which helps to understand the likelihood of asymptomatic  
302 infections or infections with mild symptoms. In the current study, the antibody prevalence of 2.9%  
303 (95% CI 2.3 to 3.6) by 5 April and 6.0% (95% CI 5.1 to 7.1) by 26 April 2020, indicates that an  
304 increasing fraction of the Belgian population has already been exposed to SARS-CoV-2. The  
305 seroprevalence estimates reported in this study are valuable to calibrate the Belgian response to the  
306 epidemic and to guide policy makers to control the epidemic wave and potential future waves and to  
307 avoid a deconfinement strategy leading to a rebound. The latter might be difficult to achieve as the  
308 current study results indicated low seroprevalences which are far from required herd immunity levels.  
309 Moreover, more research is needed to confirm if seropositivity correlates to protective immunity  
310 against the virus.

## 311 **Data sharing**

312 The authors are willing to share original data on request.

## 313 **Contributors**

314 SH, JDB and IW interpreted study results and drafted and revised the manuscript. SH also contributed  
315 to the study design and planned and performed statistical analysis. SA contributed to the study design,  
316 planned statistical analysis, interpreted study results and revised the manuscript. EE contributed to  
317 drafting the manuscript. LP and AC contributed to the study design, sample analysis and interpreted

318 the study results and revised the manuscript. SDS contributed to sample analysis and revised the  
319 manuscript. PB, PVD, NH and HT contributed to the study design, interpreted the study results and  
320 revised the manuscript. PVD and HT also conceived the study. NH also planned the conduct of  
321 statistical analysis. All authors had access to all of the data and take full responsibility for the integrity  
322 of the data, the accuracy of the data analysis, and the finished article. The corresponding author attests  
323 that all listed authors meet authorship criteria and that no others meeting the criteria have been  
324 omitted.

### 325 **Declaration of interest**

326 All authors have completed the Unified Competing Interest form available at  
327 [www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) and declare: support from research grants from GSK Biologicals,  
328 Pfizer, SANOFI, Merck, Themis, Osivax, J&J and Abbott and grants from The Bill & Melinda Gates  
329 Foundation, PATH, Flemish Government and European Union, outside the submitted work; no  
330 financial relationships with any organizations that might have an interest in the submitted work in the  
331 previous three years; no other relationships or activities that could appear to have influenced the  
332 submitted work.

### 333 **Acknowledgments**

334 This work received funding from the European Union's Horizon 2020 research and innovation  
335 program - project EpiPose (No 101003688), the European Research Council (ERC) under the  
336 European Union's Horizon 2020 research and innovation program (grant agreement 682540  
337 TransMID), the Flemish Research Fund (FWO 1150017N) and from The Antwerp University Fund;  
338 which is a community of donors who contribute to research and education with their personal  
339 commitment through a donation, gift, bequest or through academic chairs.

340 We acknowledge the Belgian laboratories that voluntarily collected sera and data for this study:  
341 Algemeen Medisch Laboratorium (AML, Antwerpen), Laboratoire Luc OLIVIER (Fernelmont),  
342 Declerck Klinisch Laboratorium (Ardooi), Klinisch Labo RIGO (Genk), Labo Anacura/Nuytinck

343 (Evergem), Labo Somedi (Heist-op-den-Berg), Labo LBS (Brussels), Laboratoire Bauduin (Enghien),

344 Medisch labo Bruyland (Kortrijk), Synlab (Luik).



345 **Figure captions**

346 **Figure 1.** Map of Belgium at municipality level, collection period 1 and 2; panel A+C: number of  
347 samples tested in each municipality, panel B+D: presence of IgG-positive (red) versus exclusively  
348 IgG-negative (green) samples in each municipality.

349 **Figure 2.** Weighted seroprevalence (A, B, C) and seroincidence (D, E, F) estimates in Belgium overall  
350 (panel A+D), by 10-year age bands (panel B+E), by sex (panel C+F).

## 351 References

- 352 1. WHO. Pneumonia of unknown cause - China. Available from:  
353 <https://www.who.int/csr/don/05-january-2020-pneumonia-of-unknown-cause-china/en/>; (accessed 5  
354 April 2020).
- 355 2. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of  
356 probable bat origin. *Nature* 2020; **579**(7798): 270–3.
- 357 3. Habibzadeh P, Stoneman EK. The Novel Coronavirus: A Bird's Eye View. *J. Occup. Environ.*  
358 *Med.* 2020; **11**(2): 65–71.
- 359 4. Chan JF-W, Yuan S, Kok K-H, et al. A familial cluster of pneumonia associated with the 2019  
360 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *Lancet* 2020;  
361 **395**(10223): 514–23.
- 362 5. WHO. Coronavirus disease (COVID-19) outbreak situation. 2020.  
363 <https://www.who.int/emergencies/diseases/novel-coronavirus-2019> (accessed 26 April 2020).
- 364 6. WHO. Coronavirus disease 2019 (COVID-19) Situation Report – 51. Available from:  
365 [https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf)  
366 [covid-19.pdf](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf); (accessed 26 April 2020).
- 367 7. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with  
368 COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; **395**(10229): 1054–62.
- 369 8. FOD. Eén gerepatrieerde landgenoot testte positief op het nieuwe coronavirus. 4 February  
370 2020 2020. [https://www.info-coronavirus.be/nl/news/gerepatrieerde-landgenoot-testte-positief-op-](https://www.info-coronavirus.be/nl/news/gerepatrieerde-landgenoot-testte-positief-op-het-nieuwe-coronavirus/)  
371 [het-nieuwe-coronavirus/](https://www.info-coronavirus.be/nl/news/gerepatrieerde-landgenoot-testte-positief-op-het-nieuwe-coronavirus/) (accessed April 23, 2020).
- 372 9. Sciensano. COVID-19 - Epidemiologische situatie. Available from: [https://covid-](https://covid-19.sciensano.be/nl/covid-19-epidemiologische-situatie)  
373 [19.sciensano.be/nl/covid-19-epidemiologische-situatie](https://covid-19.sciensano.be/nl/covid-19-epidemiologische-situatie); (accessed weekly from 11 March – 11 May  
374 2020).
- 375 10. Theeten H, Hutse V, Hoppenbrouwers K, Beutels P, P VAND. Universal hepatitis B vaccination  
376 in Belgium: impact on serological markers 3 and 7 years after implementation. *Epidemiol Infect* 2014;  
377 **142**(2): 251–61.
- 378 11. Lassaunière R, Frische A, Harboe ZB, et al. Evaluation of nine commercial SARS-CoV-2  
379 immunoassays. *medRxiv* 2020: 2020.04.09.20056325.
- 380 12. Taskforce serologie LCT. Rapportage Status validatie van ELISA en auto-analyzer antilichaam  
381 testen voor diagnostiek van SARS-CoV-2; overwegingen voor gebruik. Available from:  
382 [https://www.nvmm.nl/media/3519/20200519\\_status-en-resultaten-validatie-elisa-en-auto-](https://www.nvmm.nl/media/3519/20200519_status-en-resultaten-validatie-elisa-en-auto-analyzers_versie19052020_final.pdf)  
383 [analyzers\\_versie19052020\\_final.pdf](https://www.nvmm.nl/media/3519/20200519_status-en-resultaten-validatie-elisa-en-auto-analyzers_versie19052020_final.pdf), (accessed 20 May 2020).
- 384 13. AG E. Application of EUROIMMUN tests for COVID-19 diagnostics. 2020.  
385 [https://www.coronavirus-](https://www.coronavirus-diagnostics.com/documents/Indications/Infections/Coronavirus/YI_2606_I_UK_B.pdf)  
386 [diagnostics.com/documents/Indications/Infections/Coronavirus/YI\\_2606\\_I\\_UK\\_B.pdf](https://www.coronavirus-diagnostics.com/documents/Indications/Infections/Coronavirus/YI_2606_I_UK_B.pdf) (accessed 29  
387 April 2020).
- 388 14. Cox C. Delta Method. Encyclopedia of Biostatistics. United Kingdom: John Wiley & Sons.
- 389 15. Bureau FP. Population par province et âge, au 1er janvier. <https://www.plan.be/> (accessed 22  
390 April 2020).
- 391 16. Lumley T. survey: analysis of complex survey samples. R package version 4.0. 2020.
- 392 17. Team RC. R: A Language and Environment for Statistical Computing, R Foundation for  
393 Statistical Computing. Vienna, Austria; 2020.
- 394 18. Gidding H. Australia's national serosurveillance program. *N S W Public Health Bull* 2003; **14**(4-  
395 5): 90–3.
- 396 19. van der Heide V. Neutralizing antibody response in mild COVID-19. *Nat Rev Immunol* 2020.
- 397 20. Wu F, Wang A, Liu M, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19  
398 recovered patient cohort and their implications. *medRxiv* 2020: 2020.03.30.20047365.
- 399 21. Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: A comparison  
400 with young and middle-aged patients. *J Infect* 2020.


- 401 22. Jin J-M, Bai P, He W, et al. Gender Differences in Patients With COVID-19: Focus on Severity  
402 and Mortality. *Front Public Health* 2020; **8**(152).
- 403 23. Levesque J, Maybury DW. A note on COVID-19 seroprevalence studies: a meta-analysis using  
404 hierarchical modelling. medRxiv; 2020.
- 405 24. Stringhini S, Wisniak A, Piumatti G, et al. Repeated seroprevalence of anti-SARS-CoV-2 IgG  
406 antibodies in a population-based sample. medRxiv; 2020.
- 407 25. Folkhälsomyndigheten. Första resultaten från pågående undersökning av antikroppar för  
408 covid-19-virus. 20 May 2020. <https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2020/maj/forsta-resultaten-fran-pagaende-undersokning-av-antikroppar-for-covid-19-virus/> (accessed 25 May 2020).
- 411 26. ECDC. Coronavirus disease 2019 (COVID-19) in the EU/EEA and the UK - ninth update.  
412 Available from: <https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-rapid-risk-assessment-coronavirus-disease-2019-ninth-update-23-april-2020.pdf>, (accessed 23 April 2020).
- 414 27. WHO. "Immunity passports" in the context of COVID-19. 2020. <https://www.who.int/news-room/commentaries/detail/immunity-passports-in-the-context-of-covid-19> (accessed 6 May 2020).
- 416 28. D'Arienzo M, Coniglio A. Assessment of the SARS-CoV-2 basic reproduction number, R<sub>0</sub>,  
417 based on the early phase of COVID-19 outbreak in Italy. *Biosafety and Health* 2020.
- 418 29. Liu Y, Gayle AA, Wilder-Smith A, Rocklöv J. The reproductive number of COVID-19 is higher  
419 compared to SARS coronavirus. *J Travel Med* 2020; **27**(2).
- 420 30. Altmann DM, Douek DC, Boyton RJ. What policy makers need to know about COVID-19  
421 protective immunity. *The Lancet* 2020.
- 422



A


## Collection period 1

medRxiv preprint doi: <https://doi.org/10.1101/2020.06.08.20125179>; this version posted June 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](#).




B

## Collection period 1




C







## Collection period 2



D

## Collection period 2







**Table 1.** Description of the study population, collection period 1 and 2

		Collection period 1		Collection period 2	
		(30 March 2020-5 April 2020)		(20 April 2020-26 April 2020)	
		n	%	n	%
<b>Number of samples</b>		3910		3397	
<b>Region</b>	<b>Wallonia</b>	1511	38.6	1539	45.3
	<b>Flanders</b>	2195	56.1	1556	45.8
	<b>Brussels</b>	204	5.2	302	8.9
<b>Age in years</b>	<b>0-10</b>	36	0.9	85	2.5
	<b>10-20</b>	294	7.5	442	13.0
	<b>20-30</b>	436	11.2	375	11.0
	<b>30-40</b>	461	11.8	407	12.0
	<b>40-50</b>	468	12.0	406	12.0
	<b>50-60</b>	498	12.7	430	12.7
	<b>60-70</b>	507	13.0	426	12.5
	<b>70-80</b>	506	12.9	316	9.3
	<b>80-90</b>	493	12.6	315	9.3
	<b>≥90</b>	211	5.4	195	5.7
<b>Sex</b>	<b>male</b>	1799	46.0	1599	47.1
	<b>female</b>	2111	54.0	1798	52.9